Cedric Bogaert

Company: MyNeo

Job title: Co-Founder & Chief Executive Officer

Seminars:

What Makes Neoantigen-specific T-Cells Clinically Relevant & How to Clinically Exploit Neoantigens 12:15 pm

Immunotherapeutic manipulation of the antitumour immune response offers an attractive strategy to target genomic instability in cancer. Accurately determining the association of neoantigen immunogenicity with response to immune checkpoint inhibition relies on accurate prioritisation of immunogenic neoantigens. The workshop will cover: Emerging approaches for identifying, prioritising, and immunologically targeting personalised neoantigens Navigating how several major…Read more

day: Workshop Day